Know Cancer

or
forgot password

New Formulation of Salicylate to Improve Treatment of Common Skin Warts


Phase 4
12 Years
75 Years
Open (Enrolling)
Both
Warts

Thank you

Trial Information

New Formulation of Salicylate to Improve Treatment of Common Skin Warts


Inclusion Criteria:



- evidence of skin plantar wart(s)

Exclusion Criteria:

- iodine allergy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

To determine if salicylate with ethyl pyruvate (SA-EP) eliminates plantar warts more quickly than salicylate (SA) alone.

Outcome Description:

Subjects' wart(s) are treated with SA or SA-EP every two weeks for up to 16 weeks.

Outcome Time Frame:

16 weeks

Safety Issue:

No

Principal Investigator

Michael R Grossman, DPM

Investigator Role:

Principal Investigator

Authority:

United States: Institutional Review Board

Study ID:

R12-3128

NCT ID:

NCT01712295

Start Date:

November 2011

Completion Date:

March 2014

Related Keywords:

  • Warts
  • Warts
  • salicylic acid
  • ethyl pyruvate
  • Warts

Name

Location
Main Line Foot and Ankle Center Ardmore, Pennsylvania  19003